Acetylsalicylic acid medications in patients with asymptomatic atherosclerosis: risk or benefit?

Cover Page

Cite item

Full Text

Abstract

This review presents the problems of acetylsalicylic acid (ASA) application in general clinical practice. We showed that this was the most commonly used antiplatelet drug and it was very important to take the correlation of efficiency and risk of complications into account during the appointment of this drug. We described the problems associated with risk assessment and treatment selection in patient with subclinical atherosclerosis. We showed main associations between the different atherosclerosis markers and risk of coronary and cerebral complications; the results of meta-analysis concerning the efficiency of antiplatelet therapy. We discussed the possibilities for the prevention of the gastrointestinal tract damage. The application of the lowest effective quantity of ASA was the most important act for safe usage. The combination of ASA and small antacid doses could make its application more safety without significantly affecting the drugs efficiency.

About the authors

L. O Minushkina

Teaching and Research Medical Center Office of the President of the Russian Federation

Email: minushkina@mail.ru
проф. каф. терапии, кардиологии и функциональной диагностики ФГБУ ДПО УНМЦ 121359, Russian Federation, Moscow, ul. Marshala Timoshenko, d. 21

References

  1. Mancia G, Fagard R, Narkiewicz K et al. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2014; 23 (1): 3-16.
  2. Zanchetti A, Hansson L, Dahlöf B. Benefit and harm of low - dose aspirin in well - treated hypertensives at different baseline cardiovascular risk. J Hypertens 2002; 20 (11): 2301-7.
  3. Gallino A, Aboyans V, Diehm C et al. European Society of Cardiology Working Group on Peripheral Circulation. Non - coronary atherosclerosis. Eur Heart J 2014; 35 (17): 1112-9.
  4. Fowkes F.G, Housley E, Cawood E.H et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial claudication: ultrasound study in men at high and low risk for disease in the general population. Int J Epidemiol 1991; 20: 384-92.
  5. Nambi V, Chambless L, He M et al. Common carotid artery intima - media thickness is as good as carotid intima - media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. Eur Heart J 2012; 33 (2): 183-90.
  6. O’Leary D.H, Polak J.F, Kronmal R.A et al. Carotid - artery intima media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. New Engl J Med 1999; 340: 14-22.
  7. Bots M.L, Hoes A.W, Koudstaal P.J et al. Common carotid intima - media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432-7.
  8. Patel J, Al Rifai M, Blaha M.J et al. Coronary Artery Calcium Improves Risk Assessment in Adults With a Family History of Premature Coronary Heart Disease: Results From Multiethnic Study of Atherosclerosis. Circ Cardiovasc Imaging 2015; 8 (6): e003186.
  9. Gielen S, De Backer G, Piepoli M, Wood D ESC Textbook of Preventive Cardiology. Oxford University Press, 2015; p. 351.
  10. Vandvik P.O, Lincoff A.M, Gore . et al. Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest, 2012; 141 (Suppl. 2): e637S-e668S.
  11. Baigent C, Blackwell L, Collins R et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849-60.
  12. Conrad M.F, Boulom V, Mukhopadhyay S et al. Progression of asymptomatic carotid stenosis despite optimal medical therapy. J Vasc Surg 2013; 58 (1): 128-35.
  13. Schoenefeld E, Donas K, Radicke A et al. Perioperative use of aspirin for patients undergoing carotid endarterectomy. Vasa 2012; 41 (4): 282-7.
  14. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310 (6983): 827-30.
  15. Henry P, Vermillet A, Boval B. 24-hour time - dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105 (2): 336-44.
  16. Nonsteroidal anti - inflammatory drugs: add an anti - ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs. Prescrire Int 2011; 20 (119): 216-9.
  17. Miyamoto M, Haruma K, Okamoto T. Continuous proton pump inhibitor treatment decreases upper gastrointestinal bleeding and related death in rural area in Japan. J Gastroenterol Hepatol 2012; 27 (2): 372-7.
  18. Баркаган З.С., Котовщикова Е.Ф. Сравнительный анализ основных и побочных эффектов различных форм ацетилсалициловой кислоты. Клин. фармакология и терапия. 2004; 13 (3): 40-3.
  19. Яковенко Э.П., Краснолобова Л.П., Яковенко А.В. и др. Влияние препаратов АСК на морфофункциональное состояние слизистой оболочки желудка у кардиологических пациентов пожилого возраста. Сердце. 2013; 71 (3): 145-50.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies